Makimoto Go, Ichihara Eiki, Hotta Katsuyuki, Ninomiya Kiichiro, Oze Isao, Minami Daisuke, Ninomiya Takashi, Kubo Toshio, Ohashi Kadoaki, Tabata Masahiro, Maeda Yoshinobu, Kiura Katsuyuki
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
Acta Med Okayama. 2018 Jun;72(3):319-323. doi: 10.18926/AMO/56080.
Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating advanced non-small cell lung cancer, high-volume hydration and a long infusion time are necessary to avoid nephrotoxicity, and cisplatin-based chemotherapy has been difficult to administer in outpatient settings. A low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced, but there are no clear conclusions regarding which agent should be used. We describe our ongoing randomized phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis. This study will clarify whether mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.
尽管在治疗晚期非小细胞肺癌方面，与卡铂相比，基于顺铂的化疗显示出生存优势，但为避免肾毒性，需要大量补液和长时间输注，且基于顺铂的化疗在门诊环境中难以实施。最近引入了一种使用甘露醇或呋塞米进行强制利尿的小容量补液方法，但关于应使用哪种药物尚无明确结论。我们描述了我们正在进行的评估强制利尿疗效的随机II期试验（OLCSG1406研究）。这项研究将阐明在小容量补液的基于顺铂的化疗中，甘露醇或呋塞米哪种更合适。
